Get the Stockscreener App
18.33
0.54%
-0.10
Damora Therapeutics Inc stock is traded at $18.33, with a volume of 94,992.
It is down -0.54% in the last 24 hours and down -25.94% over the past month.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
See More
Previous Close:
$18.43
Open:
$18.59
24h Volume:
94,992
Relative Volume:
0.20
Market Cap:
$1.13B
Revenue:
Net Income/Loss:
$-209.84M
P/E Ratio:
-4.0109
EPS:
-4.57
Net Cash Flow:
$-6.73M
1W Performance:
-10.85%
1M Performance:
-25.94%
6M Performance:
-31.12%
1Y Performance:
+0.00%
1-Day Range:
$17.84
$18.89
1-Week Range:
$18.00
$21.86
52-Week Range:
$16.50
$34.89
Damora Therapeutics Inc Stock (DMRA) Company Profile
Name
Damora Therapeutics Inc
Sector
Industry
Phone
(781) 281-9020
Address
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
18.33 | 1.13B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
510.13 | 129.30B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.70 | 94.90B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.21 | 82.49B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.03 | 53.33B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
370.95 | 41.96B | 5.76B | 514.49M | 1.10B | 4.4813 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-27-26 | Initiated | Jefferies | Buy |
| Jun-11-26 | Initiated | H.C. Wainwright | Buy |
| Jun-08-26 | Initiated | TD Cowen | Buy |
| May-28-26 | Initiated | Wedbush | Outperform |
| Apr-24-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-25-26 | Initiated | Evercore ISI | Outperform |
| Feb-17-26 | Initiated | UBS | Buy |
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Damora Therapeutics Inc Stock (DMRA) Latest News
Breaking News about Damora Therapeutics, Inc.Ordinary Shares (Nasdaq:DMRA) - FinancialContent
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares - Investing.com
Damora Therapeutics CEO Jennifer Jarrett buys $252,875 in shares By Investing.com - Investing.com South Africa
Using personal funds, CEO Jennifer Jarrett buys Damora Therapeutics (DMRA) shares at $20.23 each. - Stock Titan
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Damora (DMRA) Update: Gains 1.68% to Reach $30.82 in the Current Update; Price Setup: the Near-Term Reference Band Stretches From $29.28 to $32.36 on the DayStrong Buy Stocks - vinanet.vn
Damora (DMRA) Results at a Glance: The Available Earnings Metric Delivers a Miss in the Current Update; Session Move: The Share Price Sheds 6.23% in Latest TradingEarnings Decline Risk - vinanet.vn
DAMORA THERAPEUT (DMRA) Stock News, Mar 19-23, 2026 - Stock Titan
Damora Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Is Up 5.1% After Starting CLARITY-101 mutCALR Trial Has The Bull Case Changed? - simplywall.st
Damora Therapeutics (DMRA) Starts CLARITY 101 Trial With Valuation Still In Focus - Sahm
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneVolatility Smirk - vinanet.vn
Damora Therapeutics (DMRA) Adds 1.01% as Bulls Defend Key Support ZoneDark Pool Volume - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesKAMA Signal - dars.gov.et
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesFear Greed Index - vinanet.vn
Damora Therapeutics (DMRA) Advances 1.01% to $31.04 as Biotech Sentiment SteadiesSuperTrend - careplusvn.com
Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares - kalkinemedia.com
Damora Therapeutics (DMRA) director awarded 30,350 stock options at $31.00 strike - Stock Titan
Damora Therapeutics (DMRA) files Form 3 for new director Andrew Cheng - Stock Titan
DMRA Q1 2026 Earnings: EPS Misses Estimates by 56.8% as Shares Rise 8%Fiscal Year Earnings - vinanet.vn
Equities Analysts Offer Predictions for DMRA Q3 Earnings - MarketBeat
Damora Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside - Seeking Alpha
RBC Capital Maintains Damora Therapeutics(DMRA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
DMRA SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million - scanx.trade
Damora Therapeutics Q2 Results: EPS beats estimate, losses narrow - scanx.trade
Damora Therapeutics (NASDAQ: DMRA) resets $150M ATM after Cayman redomestication - Stock Titan
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Damora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Starts DMR-001 Trial With 100 mg Monthly Dose - Stock Titan
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)? - simplywall.st
DMRA Q1 2026 Earnings: Wider-than-Expected Loss Signals Rising Clinical-Stage Cost PressuresQuarterly Earnings - vinanet.vn
Damara (DMRA): Lori Firmani plans sale of 1,800 common shares via Maxim - Stock Titan
Damora Therapeutics, Inc. Common Stock (DMRA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - marketbeat.com
Damora initiates phase 1 trial of mutCALR antibody therapy - Investing.com
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com Australia
Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis - The Manila Times
Damora initiates phase 1 trial of mutCALR antibody therapy By Investing.com - Investing.com UK
Damora Begins Testing Antibody Designed for Monthly Doses - Stock Titan
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com India
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com Australia
Damora Therapeutics earnings on deck as rare blood cancer race heats up - Investing.com
DMRA Q2'26 Earnings: EPS estimate is (0.41) USD - TradingView
Damora Therapeutics grants 451,000 stock options to six new hires - scanx.trade
Damora Therapeutics Inc Stock (DMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Damora Therapeutics Inc Stock (DMRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Firmani Lori | Officer |
Aug 05 '26 |
Proposed Sale |
31.10 |
1,800 |
55,980 |
0 |
| Winslow Garrett | General Counsel |
Jul 06 '26 |
Sale |
29.98 |
245 |
7,345 |
2,289 |
| Firmani Lori | Officer |
Jun 22 '26 |
Proposed Sale |
25.36 |
7,615 |
193,140 |
0 |
| Bruno Julianne | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
129,000 |
0 |
137,032 |
| Fairmount Funds Management LLC | Director |
Feb 09 '26 |
Option Exercise |
0.00 |
8,713,000 |
0 |
5,809,000 |
| Schambye Hans T. | Chief Executive Officer |
Jan 02 '26 |
Sale |
21.38 |
700 |
14,966 |
4,682 |
| Winslow Garrett | General Counsel |
Jan 02 '26 |
Sale |
21.38 |
255 |
5,452 |
1,854 |
| Firmani Lori | Chief Financial Officer |
Jan 02 '26 |
Sale |
21.41 |
135 |
2,890 |
931 |
5.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):